<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062737</url>
  </required_header>
  <id_info>
    <org_study_id>PR 2898</org_study_id>
    <nct_id>NCT01062737</nct_id>
  </id_info>
  <brief_title>Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis</brief_title>
  <acronym>ERADIAS</acronym>
  <official_title>Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Expanscience S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Expanscience S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the long term (three years) ability of ASU (Avocado Soya&#xD;
      unsaponifiable) to slow the decrease of radiographic JSW (Joint Space Width) in hip&#xD;
      osteoarthritis (OA). This is a randomized, double blind, comparative, parallel group study&#xD;
      versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
      Primary hip OA, fulfilling ACR criteria, patient over 45 y, painful &gt; 1 year, Lequesne's&#xD;
      index &gt; or equal to 3, with minimum JSW at the target hip &gt; 1 mm and &lt; 4 mm on pelvic&#xD;
      radiograph.&#xD;
&#xD;
      Primary criterion of efficacy:&#xD;
&#xD;
      The main criterion of efficacy is the change of JSW between baseline and end point. JSW is&#xD;
      measured on the narrowest joint on pelvic or target hip X ray by blinded reader.&#xD;
&#xD;
      Randomisation is stratified according JSW at baseline (&lt; 2,5 mm or &gt; or equal to 2,5 mm).&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      The Full Analysis Set (FAS) is defined by patients with at least one baseline value and one&#xD;
      post baseline value.&#xD;
&#xD;
      The main analysis is scheduled on FAS using a Missing At Random (MAR)with a multiple model&#xD;
      repeated measure (MMRM)to take in account missing value.&#xD;
&#xD;
      SAP (Statistical Analysis Plan) schedule to analyse JSW change as quantitative variable using&#xD;
      an ANCOVA and as qualitative variable (progressors defined as JSW loss upper than 0,5 mm)&#xD;
      using Mantel Haentzel test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The main criterion of efficacy is the change of JSW between baseline and end point. JSW is measured on the narrowest joint on pelvic or target hip X ray by blinded reader.</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ASU (Avocado Soybean Unsaponifiable)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASU</intervention_name>
    <arm_group_label>ASU (Avocado Soybean Unsaponifiable)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  primary OA of hip,&#xD;
&#xD;
          -  ACR criteria,&#xD;
&#xD;
          -  older than 45 years,&#xD;
&#xD;
          -  symptomatic painful &gt; 1 an,&#xD;
&#xD;
          -  Lequesne's index &gt; or equal to 3,&#xD;
&#xD;
          -  JSW between 1 and 4 mm on pelvic radiograph.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary OA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multiple locations</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2010</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pr Michel Lequesne</name_title>
    <organization>Principal investigator</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

